Ascelia Pharma

Oncopeptides AB

This biotech company develops targeted therapies for patients with difficult-to-treat hematological diseases, specifically focusing on multiple myeloma treatments.

VectivBio

This company develops biopharmaceutical treatments for severe rare gastrointestinal conditions, including short bowel syndrome, for patients with orphan diseases.

Minoryx

This biotechnology company develops orphan drugs and therapies for patients suffering from rare, life-threatening genetic diseases of the central nervous system.

Actelion Holding Ltd

This biopharmaceutical company develops and commercialises orphan drugs to treat rare diseases, including pulmonary arterial hypertension, for patients worldwide.

Abliva

This biopharmaceutical company develops novel medicines for patients suffering from rare and severe primary mitochondrial diseases.

Noema Pharma

This company develops clinical-stage therapeutic products for patients with central nervous system disorders and orphan neurological conditions.

Onxeo S.A. (TopoTarget A/S)

This clinical-stage biotechnology company develops oncology drugs targeting tumour DNA damage response for patients with rare cancers and unmet medical needs.

Minoryx Therapeutic

This biotech company develops therapies for orphan central nervous system diseases, such as X-linked adrenoleukodystrophy, for patients with high unmet medical needs.